Utilising integrated bio-behavioural surveillance (IBBS) to investigate declining hepatitis C antibody prevalence among people who inject drugs in the Australian Needle and Syringe Program Survey
Bibliographic Data
| ID | 14908462 |
|---|---|
| Authors | Lisa Maher (0000-0001-6020-6519, Burnet Institute, corresponding author), Handan Wand (0000-0002-8279-7652, Data61), Sue Heard (0000-0002-5211-7599, Northern Sydney Local Health District), Mitchell Starr (0000-0001-9521-7496, St Vincent's Hospital Melbourne), Farzaneh Zolala (0000-0002-1848-183X, Australian Human Rights Commission), Robert Kemp (Queensland Health), Phillip Cunningham, Philip Cunningham (0000-0003-2613-6910, St Vincent’s Private Hospital Sydney), Heidi Drummer, Heidi E Drummer (0000-0002-0042-6277, Burnet Institute), Margaret Hellard (0000-0002-5055-3266, Burnet Institute), John Kaldor (0000-0002-7639-4355, The George Institute for Global Health), Gregory J Dore (0000-0002-4741-2622, St Vincent's Clinic), Gregory Dore |
| Year | 2025 |
| Volume | 144 |
| Issue | Pt 1 |
| Pages | 104576 |
| Publication date | 2025-10-01 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | International Journal of Drug Policy (JOURNAL) |
| Journal identifiers | ISSN: 0955-3959 • E-ISSN: 1873-4758 |
| Publisher | Elsevier BV (PUBLISHER) |
| DOI | 10.1016/j.drugpo.2024.104576 |
| PMID | 39353802 |
| OpenAlex | W4402990554 |
| Language | EN |
| Citations received | 1 |
| References cited | 39 |
The temporal decline in HCV Ab prevalence appears related to reduced sensitivity of DBS HCV Ab detection with viral clearance following treatment. Since 2016, HCV treatment uptake has increased markedly including among people who inject drugs. In this context, continuing to monitor HCV Ab prevalence by DBS testing is problematic, with a shift to surveillance of active infection the most relevant to guide policy and practice in this setting
Environmental health · Hepatitis C · Psychiatry · Syringe · Hepatitis C virus research · HIV, Drug Use, Sexual Risk · HIV/AIDS Research and Interventions · Medicine · Virology
Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs
Trends in hepatitis C antibody prevalence among Aboriginal and Torres Strait Islander people attending Australian Needle and Syringe Programs, 1996–2015
Estimating the Consensus hepatitis C Cascade of Care among people who inject drugs in Australia
Housing Instability among People Who Inject Drugs
Reduction in HCV Incidence Among Injection Drug Users Attending Needle and Syringe Programs in Australia
| Citations per year | 1 |
|---|---|
| Citation span | 2025 - 2025 (1) |
| Highly cited | No |